🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🧬 We’re continuing our “Inside Immunai,” with David Brocks, Director. David leads the team building the "ChatGPT of the immune system" and thrives on the rare "eureka" moments in tech. Fun fact: He’s also a big fan of ‘Soulsborne’🎮Want to work with David? immunai.com/careers/

Inside each cell lies a unique story of immune response. On the Impact AI Podcast, our CEO Noam Solomon spoke with Heather D. Couture about how our immune atlas leverages AI & single-cell genomics for precise drug discovery. Listen here: bit.ly/3YPTssi

We’re teaming up with Teva Pharmaceuticals to bring precision to clinical trials in immunology & immuno-oncology. Using AMICA™ & IDE™, we’re improving trial decision-making by refining drug mechanisms, dose selection, and biomarker insights. More in BiopharmaTrend bit.ly/4hQXrML

Honored to be named Immunology Innovation of the Year by the BioTech Breakthrough! Our commitment to advancing immunology with AI can help pharma teams understand immune responses like never before. biotechbreakthroughawards.com/2024-winners/

In drug development, every decision counts. As highlighted in GenomeWeb by Adam Bonislawski, our partnership with Teva Pharmaceuticals is bringing immune profiling into earlier stages, unlocking new insights into autoimmune diseases genomeweb.com/cancer/teva-de…

The immune system holds valuable data for advancing medicine. Our work with Teva Pharmaceuticals uses AI and our immune cell atlas to analyze patient responses, refine dosing, and identify biomarkers—helping move therapies forward. The Cancer Letter

🧬JPM season is here! Immunai’s co-founder & CEO, will be at JPM 2025 in January to discuss how AI and our single-cell multi-omics atlas are transforming immune system insights and early R&D. Will you be there? Let us know in the comments👇

95% of drugs fail before reaching patients. Our CEO Noam Solomon joined Maayan Jaffe-Hoffman on ILTV Israel News’s Lights of Hope panel to discuss how AI and our immune cell atlas are improving clinical trial efficiency and driving better outcomes. bit.ly/3W9lDkq

What drives progress in cancer treatment? At Immunai, it starts with the team above all. Healthy debate and shared commitment power our breakthroughs in immunology and beyond. Read more from Micha Breakstone 🇮🇱🎗️ and Inc.: bit.ly/4iXx4FL

AI has massive potential in immunotherapies—so why is drug development still lagging? In HIT Consultant Media, our CEO, Noam Solomon unpacks data gaps, immune system mapping, and how AI can transform the process. Read: tinyurl.com/2fxnbk2p

Our CEO Noam Solomon is headed to Davos to represent Immunai as part of the World Economic Forum Unicorn Program with other high-growth companies shaping the future of their industries. Are you attending? tinyurl.com/2mmnvvc3

Immunai has been named Startup of the Week via The Innovator⭐️ Read how Immunai is bridging the gap between computer science and life sciences to combat Eroom’s Law—the rising costs of drug development.bit.ly/4gbnwEm

🧬 Inside Immunai kicks off 2025 with Eva Macuchova, our Scientific Team Lead! At Immunai, she’s helped standardize data & fuel AI-powered discoveries in cancer & inflammatory research. Crime novel lover, foodie, & data expert—join her team! tinyurl.com/yck83dwt

Dr. Mikael Dolsten, a leader behind 35+ approved therapies, is bringing his expertise to Immunai’s Board. His experience in R&D and immunology will help us deepen AI’s role in drug discovery, bringing new treatments to patients faster. tinyurl.com/79c4sf4v

After leading R&D at Pfizer, Dr. Mikael Dolsten is entering a new chapter. He’s joining Immunai’s board to help advance AI-powered drug development. Read about his move and outlook on the future of biopharma via PharmaVoice: tinyurl.com/352t6hxc

🧬 Heading to #AACR25? Meet Immunai CEO Noam Solomon, CTO Adeeb Rahman, & VP BD Evan Zisholtz 📌 See our April 30 poster on predicting aPD1 response using a human ex vivo tumor model + multiomic data. #Immunotherapy #CancerResearch #Multiomics

We’re teaming up with Parker Institute for Cancer Immunotherapy to build one of the largest real-world single-cell datasets. Integrated into AMICA™, this will power immune insights across cancers, accelerating discovery + reducing trial risk genengnews.com/topics/cancer/…

At #DDW2025, Immunai & AstraZeneca share new IBD research using single-cell data + functional genomics. Deleting one target reduced TNFα/IFNγ in macrophages - showing real therapeutic potential. 📷 Read more: eposters.ddw.org/ddw/2025/ddw-2…  #IBD #Immunology #DrugDiscovery #AIinBiotech

Our CEO Noam Solomon just joined a very impressive club: In Vivo, Citeline Commercial’s 2025 Rising Leaders💥 This list features 30 people shaking up biotech, medtech, and global health. Proud moment for the Immunai team. bit.ly/4m2eNZm

Excited to share our work at #BiomedIsrael! Elisha Nathan presents how Immunai de-risks immunotherapy development using AI + single-cell multi-omics. Powered by AMICA, the world’s largest clinical immune db. #Immunai #DrugDevelopment #Oncology #Autoimmune